Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Raw Materials (2020 - 2025)

Historic Raw Materials for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $24.7 million.

  • Cytek Biosciences' Raw Materials fell 803.21% to $24.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year decrease of 803.21%. This contributed to the annual value of $22.6 million for FY2024, which is 3680.78% down from last year.
  • According to the latest figures from Q3 2025, Cytek Biosciences' Raw Materials is $24.7 million, which was down 803.21% from $24.9 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Raw Materials ranged from a high of $42.2 million in Q1 2023 and a low of $15.4 million during Q3 2021
  • Over the past 5 years, Cytek Biosciences' median Raw Materials value was $26.3 million (recorded in 2022), while the average stood at $27.3 million.
  • As far as peak fluctuations go, Cytek Biosciences' Raw Materials surged by 9918.31% in 2023, and later plummeted by 3680.78% in 2024.
  • Quarter analysis of 5 years shows Cytek Biosciences' Raw Materials stood at $17.3 million in 2021, then skyrocketed by 56.0% to $26.9 million in 2022, then surged by 32.66% to $35.7 million in 2023, then crashed by 36.81% to $22.6 million in 2024, then rose by 9.22% to $24.7 million in 2025.
  • Its Raw Materials stands at $24.7 million for Q3 2025, versus $24.9 million for Q2 2025 and $23.7 million for Q1 2025.